Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02163746
Other study ID # 8606
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 14, 2015
Est. completion date June 7, 2016

Study information

Verified date February 2022
Source Henry Ford Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compares two well-known treatment options for Stage 2 hidradenitis suppurativa: carbon dioxide (CO2) laser excision versus surgical deroofing.


Description:

- We will be treating patients with Stage 2 (interconnected sinus tracts and nodules) hidradenitis suppurativa who have somewhat active involvement (including drainage) in the axillae. We will only be treating ONE axilla per patient. - After patients are screened and deemed appropriate candidates, they will be randomized to a treatment group: CO2 laser excision or surgical deroofing. - For each patient, there will be a single intervention (either CO2 laser excision or surgical deroofing), after which there will be 5 planned follow-up appointment at following intervals: 1 week, 2 weeks, 4 weeks, 3 months, 6 months. This will take place over course of 6 months for each patient. - During the study, subjects will be asked to provide information on quality of life measures, and filling out questionnaires (DLQI and Skindex29) at each visit. - Inclusion criteria: 1. Be at least 13 years old and have a diagnosis of hidradenitis affecting the underarms. 2. Agree to follow and undergo all study-related procedures, and follow-up over six month period. - Exclusion criteria: 1. Patients who have already undergone surgical excision to affected area. 2. Patients who are pregnant or breast feeding will not be able to take part in the study due to the unknown effects of CO2 laser in pregnant females, as well as risk of lidocaine use during pregnancy and breastfeeding 3. Patients with a history of allergy to lidocaine or topical anesthetics will not be able to take part in this study. 4. Patients with a history of vitiligo as the CO2 laser may cause new spots of depigmentation. 5. Patients with a pacemaker/defibrillator in place.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 7, 2016
Est. primary completion date December 20, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 100 Years
Eligibility Inclusion Criteria: 1. Be at least 13 years old 2. Be otherwise healthy 3. Have a diagnosis of HS 4. Patients must have Hurley Stage II HS affecting the axilla, with one or more widely separated recurrent abscesses, with formation of a sinus tract and/or scarring 5. Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form 6. Agree to follow and undergo all study-related procedures 7. If applicable, minors must have permission of legal guardian for participation in the study Exclusion criteria: 1. Patients with HS Hurley stage I and III will be excluded from participation 2. Patients who are pregnant or breast feeding will not be able to take part in the study due to the unknown effects of CO2 laser in pregnant females, as well as risk of lidocaine use during pregnancy and breastfeeding 3. Any reason the investigator feels the patient should not participate in the study 4. If a patient misses = 2 consecutive study visits, the patient will be excluded from further participation in this trial 5. History of allergy to lidocaine or topical anesthetics 6. Patients with a history of vitiligo as the CO2 laser may cause new spots of depigmentation 7. Patients with a pacemaker/defibrillator in place 8. Patients who have previously undergone surgical intervention and recurred in the axilla to be treated

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
CO2 (carbon dioxide) laser

Surgical Deroofing


Locations

Country Name City State
United States Henry Ford Health System Detroit Michigan

Sponsors (1)

Lead Sponsor Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of Life Measures Quality of Life measures will be measured via DLQI and Skindex29 patient surveys. June 2014-February 2014
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2